組織概要

GOTIC-015　GOTIC-VTE試験（観察研究）
Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC‐VTE trial. Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Satoshi Yamaguchi, Shoji Nagao, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toshiaki Yasuoka, Soichi Yamashita, Takashi Hirakawa, Tomonori Nagai, Yoshinobu Hamada, Masaya Uno, Mayuyo Mori‐Uchino, Michitaka Ohwada, Akira Mitsuhashi, Toyomi Satoh, Keiichi Fujiwara, Mitsuaki Suzuki, on behalf of the GOTIC-VTE Trial Investigators Journal of Thrombosis and Thrombolysis Published online: 27 November 2024 DOI:10.1007/s11239-024-03055-1
SGSG-012/
GOITC-004
後方視的研究
Re‐administration of platinum‐based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG‐012/GOTIC‐004/Intergroup study. Shoji Nagao, Shin Nishio, Kazuhiro Takehara, Shinya Sato, Toyomi Satoh, Muneaki Shimada, Satoshi Yamaguchi, Hiroshi Tanabe, Masashi Takano, Kouji Horie, Yuji Takei, Yuichi Imai, Yumi Hibino, Kosei Hasegawa, Munetaka Takekuma, Kazuto Nakamura, Hirokuni Takano, Keiichi Fujiwara, Hisashi Masuyama International Journal of Clinical Oncology Published online: 13 July 2024 DOI:10.1007/s10147-024-02585-1
GOTIC-015　GOTIC-VTE試験（介入研究）
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toyomi Satoh, Hiroya Itagaki, Takashi Hirakawa, Mayuyo Mori-Uchino, Tomonori Nagai, Yoshinobu Hamada, Soichi Yamashita, Hiroko Yano, Tomoyasu Kato, Keiichi Fujiwara, Mitsuaki Suzuki, and on behalf of the GOTIC-VTE Trial Investigators Journal of Gynecologic Oncology 2024 Jul;35(4):e37 DOI:10.3802/jgo.2024.35.e37
GOTIC-019　後方視的研究
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study Shoji Nagao, Jun Tamura, Takashi Shibutani, Miko Miwa, Tomoyasu Kato, Ayumi Shikama, Yuji Takei, Natsuko Kamiya, Naoki Inoue, Kazuto Nakamura, Aya Inoue, Koji Yamamoto, Keiichi Fujiwara, Mitsuaki Suzuki International Journal of Clinical Oncolgy DOI:10.1007/s10147-023-02329-7
GOTIC-001　JGOG 3019 試験
Intraperitoneal Carboplatin for Ovarian Cancer -A Phase 2/3 Trial Shoji Nagao, Keiichi Fujiwara, Kouji Yamamoto, Hiroshi Tanabe, Aikou Okamoto, Kazuhiro Takehara, Motoaki Saito, Hiroyuki Fujiwara, David S.P. Tan, Satoshi Yamaguchi, Sosuke Adachi, Akira Kikuchi, Takeshi Hirasawa, Takeshi Yokoi, Tomonori Nagai, Toyomi Sato, Shoji Kamiura, Akira Fujishita, Wong Wai Loong, Karen Chan, Peter Syks, Alexsander Olawaye, Sang-Young Ryu, Hiroyuki Shigeta, Eiji Kondo, Yoshihito Yokoyama, Takashi Matsumoto, Kosei Hasegawa and Takayuki Enomoto The New England Journal of Medeicine EvidenceNEJM Evid 2023;2(5) DOI:10.1056/EVIDoa2200225
GOTIC-031　Vivli試験
Feasibility of New Method for the Prediction of Clinical Trial Results Using Compressive Sensing of Artificial Intelligence GOTIC Study. Yasunari Miyagi, Keiichi Fujiwara, Hisanaga Nomura, Koji Yamamoto, Robert L Coleman British Journal of Healthcare and Medical Research Vol.10, No.1 Publication Date: February 25, 2023 Doi:10.14738/jbemi.101.14061.
GCIG Symptom Benefit Consensus Review
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. H. Woopen, J. Sehouli, A. Davis, Y.C. Lee, P.A. Cohen, A. Ferrero, N. Gleeson, A.Jhingran, Y. Kajimoto, J. Mayadev, M.P. Barretina-Ginesta, S. Sunder, N. Suzuki, E. van Dorst, F. Joly Cancer Treatment Reviews 107 (2022) 102396 Doi.org/10.1016/j.ctrv.2022.102396
GOTIC-016 JAVELIN Ovarian 200 試験
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, Amit M Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary E Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Leary, Anna V Tinker, Kyung Hae Jung, Radoslaw Madry, Sang-Yoon Park, Charles K Anderson, Fabian Zohren, Ross A Stewart, Caimiao Wei, Samuel S Dychter, Bradley J Monk Lancet Oncol. doi:10.1016/S1470-2045(21)00216-3 Published online June 15, 2021
GOTIC-013
ALIENOR 試験		Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors（The ALIENOR/ENGOT-ov7 Randomized Clinical Trial） Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, Ce´cile Dalban, Ignace Vergote, Keiichi Fujiwara, Laurence Gladieff, Hans-Joachim Lu¨ck, Anne Floquet, Annick Chevalier-Place, Andreas Schnelzer, Sandro Pignata, Fre´de´ric Selle, Jalid Sehouli, Fabien Brocard, Giorgia Mangili Patricia Pautier, Ugo De Giorgi, Magali Provansal, Pierre-Etienne Heudel JAMA Oncol. doi:10.1001/jamaoncol.2020.4574　Published online October 8.2020
GOTIC-014
PAOLA-1 /
GINECO-OV125b 試験
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial Keiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, Toyomi Satoh, Kan Yonemori, Shoji Nagao, Takashi Matsumoto, Hiroaki Kobayashi, Hughes Bourgeois, Philipp Harter, Anna Maria Mosconi, Isabel Palacio Vazquez, Alexander Reinthaller, Tomoko Fujita, Philip Rowe, Eric Pujada-Lauraine, Isabelle Ray-Coquard J Gynecol Oncol. 2021 Sep;32(5):e82　doi:10.3802/jgo.2021.32.e82 Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. Ray-Coquard I, Pautier P, Pignata S, Pe´rol D, Gonza´lez-Marti´n A, Berger R, Fujiwara K, Vergote I, Colombo N, Ma¨enpa¨a¨ J, Selle F, Sehouli J, Lorusso D, Guerra Ａli´a E M, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme´ F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. N Engl J Med 2019 Dec; 381:2416-2428. Doi:10.1056/NEJMoa1911361

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje Belau, Jean-Pierre Lotz, Martina Gropp-Meier, Laurence Gladieff, Hans-Joachim Lück, Sophie Abadie-Lacourtoisie, Eric Pujade-Lauraine, Isabelle Ray-Coquard International Journal of Gynecological Cancer 2023;0:1-9. doi: 10.1136/ijgc-2023-004995

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles Christian Pozzorini, Gregoire Andre, Tommaso Coletta, Adrien Buisson, Jonathan Bieler, Loïc Ferrer, Rieke Kempfer, Pierre Saintigny, Alexandre Harlé, Davide Vacirca, Massimo Barberis, Pauline Gilson, Cristin Roma, Alexandra Saitta, Ewan Smith, Floriane Consales Barras, Lucia Ripol, Martin Fritzsche, Ana Claudia Marques, Amjad Alkodsi, Ray Marin, Nicola Normanno, Christoph Grimm, Leonhard Müllauer, Philipp Harter, Sandro Pignata, Antonio Gonzalez-Martin, Ursula Denison, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Adrian Willig, Eric Pujade-Lauraine, Pierre-Alexandre Just, Isabelle Ray-Coquard and Zhenyu Xu Cell Reports Medicinee 4, 101344 December 19, 2023 doi: 10.1016/j.xcrm.2023.101344

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma Yann Christinat, Liza Ho, Sophie Clément, Catherine Genestie, Jalid Sehouli, Saverio Cinieri, Antonio Gonzalez Martin, Ursula Denison, Keiichi Fujiwara, Ignace Vergote, Germana Tognon, Sakari Hietanen, Isabelle Ray-Coquard, Eric Pujade-Lauraine and Thomas A. McKee JCO Precision Oncology 7:e2200555, 2023 doi: 10.1200/PO.22.00555

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial Celine Callens, Manuel Rodrigues, Adrien Briaux, Eleonore Frouin, Alexandre Eeckhoutte, Eric Pujade-Lauraine, Victor Renault, Dominique Stoppa-Lyonnet, Ivan Bieche, Guillaume Bataillon, Lucie Karayan-Tapon, Tristan Rochelle, Florian Heitz, Sabrina Chiara Cecere, Maria Jesús Rubio Pérez, Christoph Grimm, Trine Jakobi Nøttrup, Nicoletta Colombo, Ignace Vergote, Kan Yonemori, Isabelle Ray-Coquard, Marc-Henri Stern and Tatiana Popova3 Oncogene (2023) 42:3556-3563 doi: 10.1038/s41388-023-02839-8
GCIG Symptom Benefit Brainstorming MeetingIncorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, De Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M, on behalf of the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee Gynecol Oncol. 2021(161)502-507 doi:10.1016/j.ygyno.2021.02.018
GOTIC-011
後方視的研究		Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011). Sakurai M, Satoh T, Nakamura Y, Takei Y, Takahashi S, Fujiwara H, Nakamura K, Kanuma T, Fujiwara K and Suzuki M J. Obstet. Gynaecol. Res. 2021 doi:10.1111/jog.14760
GOTIC-014 PAOLA-1 /
GINECO-OV125b　試験		 Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. Ray-Coquard I, Pautier P, Pignata S, Pe´rol D, Gonza´lez-Marti´n A, Berger R, Fujiwara K, Vergote I, Colombo N, Ma¨enpa¨a¨ J, Selle F, Sehouli J, Lorusso D, Guerra Ａli´a E M, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme´ F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. N Engl J Med 2019 Dec; 381:2416-2428. Doi:10.1056/NEJMoa1911361
GOTIC-003
iPLAS 試験		A phaseⅡrandomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer. (GOTIC003/intergroup study)
Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M. Int. J. Clin Oncol. 2019 Oct; 24(10):1284-1291. doi: 10.1007/s10147-019-01471-5
GOTIC-012 / ANZGOG 0701
Symptom Benefit試験		Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.
Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.
2017.10.019. Epub 2017 Oct 26.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.
Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047 Epub 2017 Jun 8.
GOTIC-006
後方視的研究		Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. (GOTIC Study) Nakamura K, Kitahara Y, Satoh T, Takei Y, Takano M, Nagao S, Sekiguchi I, Suzuki M. World J Surg Oncol. 2016;14:173. doi: 10.1186/s12957-016-0931-4
GOTIC-007
後方視的研究		Evaluation of endometrial cytology: cytohistological correlations in 1,441 cancer patients. Fujiwara H, Takahashi Y, Takano M, Miyamoto M, Nakamura K, Kaneta Y, Hanaoka T, Ohwada M, Sakamoto T, Hirakawa T, Fujiwara K, Suzuki M. Oncology. 2015;88(2):86-94. doi: 10.1159/000368162
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-S95. doi: 10.1097/IGC.0000000000000297
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Fujiwara H, Yokota H, Monk B. Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S96-S101. doi: 10.1097/IGC.0000000000000263
GCIG Rare Tumour Consensus ReviewGynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-S108. doi: 10.1097/IGC.0000000000000262
GOITC-005
後方視的研究		Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M. Br J Cancer. 2013 Oct 1;109(7):1760-1765. doi: 10.1038/bjc.2013.521
SGSG-012/
GOITC-004
後方視的研究		Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J. Gynecol Oncol. 2013 Dec;131(3):567-573. doi: 10.1016/j.ygyno.2013.09.021

↑ページトップに戻る↑